SCHEMBL13627909

SCHEMBL13627909

O=C1/C(=N\O)c2cc(Br)ccc2N1Cc1ccccc1[N+](=O)[O-]

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.74
GSK3B P49841 3/20 0.44
CASP1 P29466 2/20 0.44
CASP3 P42574 2/20 0.44
CASP7 P55210 2/20 0.44
CASP6 P55212 2/20 0.44
ALDH1A1 P00352 3/20 0.44
ALDH2 P05091 1/20 0.44
ALDH3A1 P30838 1/20 0.44
UCHL1 P09936 2/20 0.43
UCHL3 P15374 2/20 0.43
CA2 P00918 3/20 0.43
CA1 P00915 2/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
TYR P14679 1/20 0.40
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627935 0.87 ACHE (0.55) ACHEGSK3BCASP1CASP3CASP7
SCHEMBL13627925 0.87 ACHE (0.74) ACHEGSK3BCASP1CASP3CASP7
SCHEMBL13627949 0.87 ACHE (0.55) ACHEGSK3BCASP1CASP3CASP7
SCHEMBL13627899 0.86 ACHE (0.56) ACHEGSK3BCASP1CASP3CASP7
SCHEMBL13627907 0.82 CA1 (0.49) ACHEALDH1A1ALDH2ALDH3A1UCHL1
SCHEMBL13627904 0.80 ACHE (0.53) ACHECASP1CASP3CASP7CASP6
SCHEMBL13627900 0.79 ALDH1A1 (0.69) ACHEALDH1A1ALDH2ALDH3A1UCHL1
SCHEMBL13627916 0.76 CASP1 (0.51) ACHECASP1CASP3CASP7CASP6
SCHEMBL13627910 0.73 CASP1 (0.72) ACHECASP1CASP3CASP7CASP6
SCHEMBL18954615 0.72 ACHE (0.73) ACHEGSK3BCASP1CASP3CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ACHE 4079/4885GSK3B 266/4885CASP1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.